Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyFlorida Blue specialty drug coverage & PA | OpenPa…
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    New-to-market and Self-Administered Specialty Drug Coverage List

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists newly marketed and self-administered specialty medications and indicates coverage controls (Limited Distribution Drug, Prior Authorization, Quantity Limits) and plan-specific notes relevant to Florida Blue members and providers.

    Policy Summary
    PayerFlorida Blue
    PolicyNew-to-market and Self-Administered Specialty Drug Coverage List
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry is annotated with 'PA' and refer to the member contract and Prior Authorization Program Information and Forms for guidance.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multiplelisted specialty drugs
    LDD, PA, QLcommon coverage flags

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CVS/Caremarkpreferred hemophilia pharmacy
    somenot-covered entries

    Coverage Criteria and Annotations

    Illustrative coverage flag criteria

    Coverage stance is indicated per drug using flags; newly marketed drugs require Pharmacy & Therapeutics (P&T) Committee review before a coverage determination is made.

    Coverage stance is indicated on each drug entry using one or more flags (e.g., LDD, PA, QL, NOT COVERED).
    Newly marketed prescription medications may not be covered until the Pharmacy & Therapeutics Committee reviews the medication to determine coverage and tier placement.

    ALL of the following

    • Examples

      • Abilify Maintena — LDD
      • abiraterone (abirtega) — PA, QL
      • Acthar Gel — LDD, PA, QL
      • Selected hemophilia products — PA; preferred pharmacy: CVS/Caremark
      • Some listed items — NOT COVERED (applies to specific NDCs/brands as listed)
    Refer to the New to Market Drug list for the current set of newly marketed medications pending P&T review.

    Coverage annotations and operational rules

    Drugs are annotated individually; common policy stances and operational rules are described below.

    PA (Prior Authorization): Drug entries annotated with 'PA' require prior authorization before coverage is approved.
    LDD (Limited Distribution Drug): Drug entries annotated with 'LDD' are limited distribution drugs with specific dispensing pharmacies identified; the appropriate dispensing location is listed separately.
    QL (Quantity Limit): Drug entries annotated with 'QL' are subject to quantity limits per policy-defined rules.
    NOT COVERED designation: NOT COVERED entries: Drugs annotated 'NOT COVERED' are excluded from coverage under the pharmacy benefit as listed (may apply to specific NDCs/brands).
    Preferred specialty pharmacy for hemophilia products: CVS/Caremark is the preferred in-network pharmacy for hemophilia products; hemophilia-related products are flagged with a special notation.

    Coverage Codes and Coding Notes

    Coverage control codes used in listmixed
    LDDLimited Distribution Drug (dispensing pharmacy specific)
    PAPrior Authorization required
    QLQuantity Limit
    coverage flagsmixed
    LDDLimited Distribution Drug (dispensing pharmacy identified separately)
    PAPrior Authorization required
    QLQuantity Limit applies
    NOT COVEREDDrug not covered
    Hemophilia pharmacy preference note
    Notation value2
    MeaningCVS/Caremark is the preferred in‑network pharmacy for hemophilia products
    Where shownAppears next to hemophilia-related product entries in the drug list (notation '2')

    Provider Actions, Prior Authorization, and Dispensing

    Prior Authorization

    Prior Authorization and Distribution controls

    Prior Authorization (PA) and Quantity Limit (QL) requirements apply to many specialty drugs; certain specialty drugs may be Limited Distribution Drugs (LDD) and available only from specific pharmacies. Members and providers should refer to the member contract and Prior Authorization Program Information and Forms and contact Customer Service for questions.

    • PA and QL are applied to many listed specialty drugs (see drug table entries).
    • LDD denotes drugs available only from specific dispensing pharmacies; the appropriate dispensing pharmacy can be found at the Limited Distribution Drugs link.
    • Contact Customer Service or consult the member contract and PA program forms for plan-specific applicability.
    Billing Rule

    Key Definitions and Glossary

    LDD — Limited Distribution Drug
    TermLDD (Limited Distribution Drug)
    DefinitionDrug available via a limited set of dispensing pharmacies; specific dispensing pharmacy information is identified separately (see Limited Distribution Drugs).
    Where indicatedMarked as 'LDD' alongside drug entries in the Self‑Administered Specialty Drugs lists
    PA — Prior Authorization
    TermPA (Prior Authorization)
    DefinitionCoverage for the drug requires prior authorization before approval under the pharmacy benefit.
    Operational note
    Policy Summary
    PayerFlorida Blue
    PolicyNew-to-market and Self-Administered Specialty Drug Coverage List
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry is annotated with 'PA' and refer to the member contract and Prior Authorization Program Information and Forms for guidance.
    SourceLink
    On This Page
    Coverage Criteria and AnnotationsCoverage Codes and Coding NotesProvider Actions, Prior Authorization, and DispensingKey Definitions and Glossary
    Operational note: PA requirements, plan coverage, member cost share, and pharmacy routing may vary by plan; consult the member contract, Prior Authorization Program information and forms, and Customer Service for questions.

    Preferred specialty pharmacy — hemophilia products

    CVS/Caremark is the preferred in-network pharmacy for hemophilia products; hemophilia-related products are flagged with a special notation (2) in the drug list.

    • Hemophilia products in the list include the notation '2' to indicate CVS/Caremark preference.
    • Member cost share may be higher for self‑administered specialty drugs not obtained at in‑network specialty pharmacies.
    Prior Authorization

    Prior Authorization and Distribution Constraints

    Many listed specialty drugs are subject to Prior Authorization (PA) and Quantity Limits (QL); Limited Distribution Drugs (LDD) indicate dispensing constraints and specific pharmacy routing.

    • Drug entries annotated with 'PA' require prior authorization before coverage is approved.
    • Drug entries annotated with 'QL' are subject to quantity limits.
    • Drug entries annotated with 'LDD' are limited distribution drugs with specific dispensing pharmacies.
    PA is applied to many specialty drugs and is shown as 'PA' next to drug names in the list.
    QL — Quantity Limit
    TermQL (Quantity Limit)
    DefinitionThe drug is subject to a quantity limit per policy-defined rules; indicated as 'QL' in the drug list.
    Operational noteApplied commonly with PA and/or LDD flags for specialty medications.
    LDD / PA / QL — Common drug list flags
    LDDLimited Distribution Drug — dispensing pharmacy identified separately (marked 'LDD').
    PAPrior Authorization required before coverage approval (marked 'PA').
    QLQuantity Limit applies (marked 'QL').
    NOT COVEREDDrug explicitly excluded from coverage when annotated 'NOT COVERED'.
    Coverage and dispensing notes
    Administration typesDrugs are listed as covered when self‑administered or provider‑administered specialty pharmacy products.
    Preferred specialty pharmacyCVS/Caremark is the preferred in‑network pharmacy for hemophilia products (notation '2').
    Operational implicationProviders/members should follow dispensing routing and PA requirements as annotated on each drug entry.